Notícias e Atividades da Neoleukin Therapeutics

Neoleukin Therapeutics é uma empresa listada sob o símbolo NLTX (US).

Veja o organograma con seus 11 executivos principais

Biografias mais buscadas da Neoleukin Therapeutics

• Erin Lavelle, Director
• Sarah Noonberg, Board Member
• Cantey Boyd, Board Member

Criar um alerta
para seguir os movimentos de executivos da Neoleukin Therapeutics.

Neoleukin Therapeutics possui 2.348 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Genus (Reino Unido).

Popular M&A news in Biotecnologia

• Maxion Therapeutics acaba de anunciar uma arrecadação de fundos de 72 milhões de dólares. (publicado em 3 de abril de 2025).
• Lantheus Holdings adquiriu Evergreen Theragnostics (publicado em 2 de abril de 2025).
• Isomorphic Labs acaba de anunciar uma arrecadação de fundos de 600 milhões de dólares. (publicado em 2 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Neoleukin Therapeutics

• Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference | Neoleukin Therapeutics, Inc.
• Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022 | Neoleukin Therapeutics, Inc.
• Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab) | Neoleukin Therapeutics, Inc.
• Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update | Neoleukin Therapeutics, Inc.
• Neoleukin Therapeutics to Present at Upcoming Investor Conferences | Neoleukin Therapeutics, Inc.
• Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting | Neoleukin Therapeutics, Inc.
• Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference | Neoleukin Therapeutics, Inc.
• Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel | Neoleukin Therapeutics, Inc.
• Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting | Neoleukin Therapeutics, Inc.
• Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update | Neoleukin Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Neoleukin Therapeutics

• Neoleukin Therapeutics na Wikipedia, Google News e Yahoo Finance
• Neoleukin Therapeutics na LinkedIn, Twitter e YouTube